Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Pharmaxis Ltd ( (AU:SNT) ) is now available.
Syntara Limited announced an investor webinar to discuss the next stages of clinical development for its lead drug candidate, amsulostat, which is being studied for myelofibrosis and myelodysplastic syndrome. The webinar aims to provide insights into the company’s progress and future plans, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company based in Sydney, Australia, focusing on extracellular matrix dysfunction. The company leverages its expertise in amine oxidase chemistry to develop novel medicines for blood cancers and conditions related to inflammation and fibrosis. Syntara’s lead candidate, amsulostat, targets bone marrow cancer myelofibrosis and has received Fast Track Designation, FDA Orphan Drug Designation, and clearance for development. The company is also advancing other drug candidates for various fibrotic and inflammatory diseases.
Average Trading Volume: 9,779,384
Technical Sentiment Signal: Hold
Current Market Cap: A$92.78M
For detailed information about SNT stock, go to TipRanks’ Stock Analysis page.